Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-05

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effectiveness of a multi-gene panel to determine which subjects are likely to respond to renal denervation therapy with Medtronic's Symplicity Spyral™ multi-electrode renal denervation system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

NCT02439775

Hypertension Vascular Diseases Cardiovascular Diseases

COMPLETED NA

Genetic Based Analysis in Hypertensive Patients

NCT04321044

Hypertension Renal Denervation Genetic Predisposition

COMPLETED NA

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674

Hypertension Vascular Diseases Cardiovascular Diseases +2 more

ACTIVE_NOT_RECRUITING NA

Renal Denervation in Patients With Refractory Hypertension

NCT00664638

Hypertension

COMPLETED NA

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

NCT02439749

Hypertension Vascular Diseases Cardiovascular Diseases

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to assess if renal denervation (RDN) effectiveness using the Symplicity SpyralTM multi-electrode renal denervation system is associated with ranked genomic scoring from the Geneticure multi-gene algorithm for renal denervation. The present study will assess if subjects who have a high genetic score, based on the hypothesized importance of the organ systems involved, will have differential responsiveness to RDN in a descending order. The genetic scoring is collectively ranked in a specific order, in that:

* Subjects with a "high level of general functionality" (functionality in the sympathetic nervous system (SNS), cardiac, vascular (renin-angiotensin-aldosterone system (RAAS)), and renal system genotypes will be most responsive to RDN.
* Subjects with high number of functional genotypes of SNS, cardiac, and RAAS will be the next most responsive group.
* Subjects with functionality in genotypes of SNS and cardiac systems will demonstrate the next most responsive group.
* Subjects with functionality in the SNS genotypes will demonstrate some degree of responsiveness.
* Subjects with functionality in the renal system, but not SNS, cardiac, nor RAAS, will be the least responsive to this therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RDN Patients

Patients who have received renal denervation with the Medtronic SymplicitySpyral device will have DNA collected in using a buccal swab.

Geneticure for RDN Genetic Panel

Intervention Type GENETIC

This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Geneticure for RDN Genetic Panel

This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individual is currently or has previously been enrolled in a Medtronic clinical study utilizing the Symplicity Spyral™ multi-electrode renal denervation system.
2. Subject received Renal Denervation.
3. Subject has met the primary efficacy endpoint for the Medtronic Symplicity Spyral study and which arm they were randomized to.
4. Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.